Adjusting the TMIST study design to accommodate slower than expected accrual: ECOG-ACRIN EA1151. A phase 3 study to determine the breast cancer risk reducing effect of denosumab in women carrying a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results